Schering-Plough at underperform by Bear Stearns

Schering-Plough Corp. was rated at underperform with a $14 fair value per share target by Bear Stearns analyst John Boris after the court refused to block generic Flonase sales as the temporary restraining order expires. Bear Stearns maintains its estimate of 2007 Nasonex sales of $580 million. Shares of the Kenilworth, N.J., pharmaceutical company were down 8 cents, or 0.44%, at $18.04 on volume of 6,207,100 shares versus the three-month running average of 7,278,200 shares. (NYSE: SGP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.